News | Remote Monitoring | March 14, 2016

New Biotronik Insertable Cardiac Monitor Available in the U.K. and Ireland

Implantable device provides accurate daily transmission of cardiac electrical data for arrhythmia detection

Biotronik, BioMonitor 2, AF remote monitoring, atrial fibrillation, U.K. and Ireland

March 14, 2016 — Biotronik announced that its BioMonitor 2 heart monitor is now available for patients in the United Kingdom. The insertable device allows highly accurate and reliable continuous detection of cardiac electrical events.

The monitor is indicated for patients suffering from unexplained syncope, and to detect atrial fibrillation (AF). Diagnosing the irregular heartbeat condition AF is notoriously difficult, as is finding the root cause of syncope — a condition where the patient passes out due to decreased blood flow to the brain. If left untreated, both can be life threatening.

In response, BioMonitor 2 can be inserted under the skin of the patient in a simple procedure. It then records all cardiac electrical events. Data from the device is transmitted directly to the physician via Biotronik Home Monitoring, where they are given an accurate map of the heart’s activity right on their computer screen.

“AF is often so sporadic and unpredictable that it is sometimes impossible to diagnose at the time the patient has symptoms,” commented Riyaz Kaba, M.D., from Ashford and St Peter’s Hospitals, Surrey, and St George’s Hospital, London. “It is similar with syncope. The patient can hardly choose to faint when they are hooked up to an ECG just so we can find out what’s causing it. But, because BioMonitor 2 is always on and always recording, we can see exactly what’s going on with their cardiac rhythm in these precise moments. It’s really unprecedented and the accuracy of the readings has exceeded our expectations. We get a clear picture very early on, meaning necessary treatment can begin earlier.”

As well as its diagnostic benefits, the device has been designed with the patient anatomy in mind. “The insertion procedure is easy for both doctor and patient. It only takes a few minutes,” explained Kaba. “The monitor adapts to the patient’s anatomy, and they’re satisfied with the overall cosmetic result.”

BioMonitor 2 also has Biotronik ProMRI technology and is approved for full-body magnetic resonance imaging (MRI) scans at both the usual 1.5 and ultra-high 3.0 tesla strength. Its average battery life is four years, topping the industry standard by a year.

For more information: www.biotronik.com

Related Content

The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations. #AHA #AHA20 #AHA2020

The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evalu
The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting. #AHA #AHA20 #AHA2020

The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — Atrial fibrill...
The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  #AHA #AHA2020 #AHA20

The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 – Doctors from the Mo...

The study used cadaver hearts that were images with contrast enhanced MRI and the images used to create a 3-D computation model of the electrical activation in the heart and how it was influenced by adenosine and ablation. Find more images in the original article

News | Atrial Fibrillation | October 08, 2020
October 8, 2020 – People who suffer from persistent atrial fibrillation in the heart may find relief from a new treat
The TactiFlex PAF investigational device exemption (IDE) study will evaluate he investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) to treat people suffering from paroxysmal atrial fibrillation (PAF). 

The TactiFlex PAF investigational device exemption (IDE) study will evaluate he investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) to treat people suffering from paroxysmal atrial fibrillation (PAF). 

News | Atrial Fibrillation | August 04, 2020
August 4, 2020 — Abbott announced the first enrollments in the TactiFlex PAF  investigational device exemption (IDE)
PREDICT-AF trial showed first time there is extensive extracellular matrix remodeling. #HRS2020 #Heartrhythm2020. Marilyn Fornell
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Structural changes of the atrium may occur long before the onset of atrial fibrillation (AF), and the
Results of the Atrial Fibrosis Predicts Recurrent Stroke Or New Atrial Fibrillation In Patients With Embolic Stroke Of Undetermined Source - A Multi-Center Study at HRS 2020. #HRS2020 #Heartrhythm2020,
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Atrial disease has been implicated in embolic stroke of undetermined source (ESUS) and a late-breaking